
    
      This is a prospective, randomized, double blind placebo controlled Phase 3 trial of oral
      axitinib starting at 5 mg twice daily given 3 years vs. placebo.

      Approximately 700 patients will be randomized in a 1:1 ratio between axitinib vs placebo.
    
  